- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: infusion reaction (Pubmed Central) - Mar 3, 2022
No abstract available
- |||||||||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Combination therapy, Metastases: Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN (clinicaltrials.gov) - Mar 2, 2022
P2, N=48, Active, not recruiting,
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Effect of Covalent Photoconjugation of Affibodies to Epidermal Growth Factor Receptor (EGFR) on Cellular Quiescence. (Pubmed Central) - Mar 1, 2022
The distribution of cells in each phase of the cell cycle was determined, and cells conjugated with the affibody demonstrated an accumulation in the G1 phase, indicative of G1 cell cycle arrest. Finally, the proliferative capacity of the cells was determined by the incorporation of 5-ethynyl-2-deoxyuridine (EdU) and Ki67 Elisa assay, which showed that the percentage of proliferative cells with photoconjugated affibody was half of that found for the untreated control.
- |||||||||| utomilumab (PF-05082566) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 28, 2022
P1, N=42, Active, not recruiting,
https://www.crd.york.ac.uk/prospero/, identifier CRD42019127772. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- |||||||||| anzurstobart (BMS-986351) / BMS, Erbitux (cetuximab) / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy, Metastases: CC-95251-ST-001: A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP?, in Participants With Advanced Solid and Hematologic Cancers (clinicaltrials.gov) - Feb 28, 2022
P1, N=230, Recruiting,
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Nov 2024 --> Aug 2025 | Trial primary completion date: Nov 2022 --> Jun 2024
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Evaluation of Fluorescence Intensity and Antitumor Effect Using Real-Time Imaging in Photoimmunotherapy. (Pubmed Central) - Feb 27, 2022
Cetuximab-PIT for A431 xenografts was performed at multiple doses from 0-100 J/cm...These results suggest that the rate of decay of the tumor fluorescence intensity correlates with the antitumor effect by real-time fluorescence imaging during PIT. In addition, when the fluorescence intensity of the tumor plateaued in real-time fluorescence imaging, it was assumed that the laser dose was necessary for treatment.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Review, Journal, Adverse events, Serious adverse event: Tolerability on Serious Adverse Events of First-Line Bevacizumab and Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. (Pubmed Central) - Feb 26, 2022
First-line bevacizumab-based chemotherapy substantially lowered the risks of adverse events related to the dermatological (RR 0.24, 95% CI: 0.11-0.53, p < 0.00001) and renal systems (RR 0.57, 95% CI: 0.37-0.86, p = 0.007), while significantly increasing the incidence of cardiovascular adverse events (RR 4.65, 95% CI: 1.83-11.78, p = 0.001). Thus, first-line cetuximab-based chemotherapy increases patient susceptibility to dermatological and renal adverse events, especially with rash and electrolyte disorders, whereas bevacizumab-based chemotherapy increases cardiovascular risks such as hypertension and arrhythmia.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: "Clickable" ZIF-8 for Cell-Type-Specific Delivery of Functional Proteins. (Pubmed Central) - Feb 24, 2022
In this Letter, by using zeolitic imidazolate framework-8 (ZIF-8) as protein-encapsulated nanoparticles and simultaneous doping with norbornene-modified imidazole (MIM-Nor), followed by surface attachment of the resulting nanoparticles with cetuximab (Cet) through click chemistry, we successfully synthesized Cet@protein@ZIF-8N, which was subsequently used for the selective intracellular delivery of functional proteins to epidermal-growth-factor-receptor (EGFR)-overexpressed cells...Furthermore, the same strategy was successfully applied to cell-type-specific gene editing through the delivery of a Cas9/sgRNA complex to knockdown the endogenous expression of glutathione peroxidase (GPX4), a key protein in ferroptosis. Our new system thus has potential implications in future cancer treatment and the development of precision medicine.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, MRI: Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition. (Pubmed Central) - Feb 23, 2022
Here, we report the use of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), with tumor penetration of the contrast agent gadobutrol used as a surrogate, to improve physiologically based pharmacokinetic model (PBPK) predictions of cetuximab pharmacokinetics in epidermal growth factor receptor (EGFR) positive xenografts...DCE-MRI may be a useful clinical tool in improving the prediction of antibody pharmacokinetics in solid tumors. Further studies are warranted to evaluate the utility of the DCE-MRI approach to additional mAbs and additional drug modalities.
- |||||||||| Krazati (adagrasib) / BMS
Enrollment change, Trial completion date, Trial primary completion date, Metastases: Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 (clinicaltrials.gov) - Feb 22, 2022
P1/2, N=740, Recruiting,
For peritoneal metastasis from left colon cancer, the management with CRS + lobaplatin HIPEC and rechallenge of systemic chemotherapy plus targeted medicine based on gene detection can dramatically improve prognosis and extend the overall survival. N=565 --> 740 | Trial completion date: Dec 2022 --> Sep 2023 | Trial primary completion date: Mar 2022 --> Dec 2022
- |||||||||| Trial primary completion date: MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer (clinicaltrials.gov) - Feb 21, 2022
P=N/A, N=250, Not yet recruiting,
N=565 --> 740 | Trial completion date: Dec 2022 --> Sep 2023 | Trial primary completion date: Mar 2022 --> Dec 2022 Trial primary completion date: Jul 2023 --> Oct 2023
- |||||||||| BI 765063 / Boehringer Ingelheim, BI 836880 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
New P1 trial, Combination therapy, Metastases: A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (clinicaltrials.gov) - Feb 20, 2022
P1, N=150, Not yet recruiting,
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Air in the Neck (Area D, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_3320;
Here we present a case of anterior tracheal perforation with associated Streptococcus anginosus infection in a patient undergoing chemoradiation.Case presentation 74 year old man with hypertension, coronary artery disease and stage IVA (cT3N2bMx) squamous cell carcinoma(SCC) of the left pyriform sinus on chemoradiation (Cisplatin and later on transitioned to Cetuximab; radiotherapy total dose of 6996 cGy in 33 fractions to the hypopharynx/esophagus) presented to the emergency room after developing acute toxic metabolic encephalopathy with associated progressive desaturations...He was started on broad spectrum antibiotics with Vancomycin and Cefepime...The patient completed a course of 10 days with Ceftriaxone and Vancomycin with clinical improvement and rapid transition to tracheostomy collar and good tolerance of Passy Muir valve.Discussion Tracheal injury mechanisms are diverse and include infection, chemotherapy, radiation and trauma...5The patient’s prior diagnosis of SCC of the left pyriform sinus and the ongoing chemoradiation were most likely involved in the development of this complex infection. To our knowledge, this is the only case of Streptococcus anginosus associated with non-traumatic anterior tracheal perforation that has been published to date.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial completion date, Trial primary completion date, Metastases: Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Feb 18, 2022
P1/2, N=4, Completed,
To our knowledge, this is the only case of Streptococcus anginosus associated with non-traumatic anterior tracheal perforation that has been published to date. Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Feb 2022 | Trial primary completion date: Jan 2024 --> Feb 2022
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Aliqopa (copanlisib) / Bayer
Clinical, P1 data, Journal, Combination therapy: Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. (Pubmed Central) - Feb 17, 2022
P1/2
Among eight evaluable patients for response, four patients (50%) had disease stabilization according to RECIST1.1 as best response. Conclusion Copanlisib combined with cetuximab demonstrated unfavorable toxicity and limited efficacy in heavily pretreated recurrent and/or metastatic HNSCC patients.Trial registration NCT02822482, Date of registration: June 2016.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Clinical data, Journal: Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. (Pubmed Central) - Feb 17, 2022
Together, we revealed concurrent genetic alterations in the PI3K pathways in NF1-mutant tumors, suggesting the need to simultaneously block MAPK and PI3K pathways in treatment. The potential of NF1 alteration as a novel biomarker for targeted therapy was highlighted, warranting further investigations in clinical settings.
- |||||||||| Ibrance (palbociclib) / Pfizer, Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Metastases: Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Feb 16, 2022
P1, N=24, Active, not recruiting,
The potential of NF1 alteration as a novel biomarker for targeted therapy was highlighted, warranting further investigations in clinical settings. Trial completion date: Jan 2022 --> Jul 2023
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: An overview of diagnosis and management of drug-induced hypomagnesemia. (Pubmed Central) - Feb 12, 2022
In recent years, the mechanisms of drug-induced hypomagnesemia have been unraveled through the discovery of key Mg transporters in the gut and kidney. This narrative review of available literature focuses on the pathogenetic mechanisms underlying drug-induced hypomagnesemia in order to increase the insight of clinicians toward early diagnosis and effective management.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: EGF/EGFR signaling blockage inhibits tumor cell-derived exosome uptake by oral squamous cell carcinoma through macropinocytosis. (Pubmed Central) - Feb 12, 2022
These EGFR inhibitors also suppressed OSCC cell-derived exosome-induced proliferation, migration, invasion, stemness, and chemoresistance of OSCC cells. Taken together, the data present herein suggest that EGFR inhibitors might inhibit the malignant potential of OSCC cells through direct inhibition of not only EGFR downstream signaling pathway but also cellular uptake of OSCC cell-derived exosomes through macropinocytosis.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Review of systemic chemotherapy in unresectable colorectal peritoneal carcinomatosis. (Pubmed Central) - Feb 11, 2022
However, there is significant heterogeneity in the trial data, lack of prospective randomized controlled trials and demonstrated treatment variability based on age and tumour characteristics. This review summarises the current literature in regard to treatment in the unresectable CPC setting as well as discussing issues with the current data and highlighting the need for further trials.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Journal: Rapid Production of Bispecific Antibodies from Off-the-Shelf IgGs with High Yield and Purity. (Pubmed Central) - Feb 11, 2022
Binding assays and T cell-mediated cytolysis assays were performed to validate the binding and functional properties of Trastuzumab × Cetuximab BsAb and Cetuximab × OKT3 BsAb, respectively. This approach enables rapid, low-cost production of highly homogeneous tetravalent BsAbs in a modular fashion, presenting an opportunity to quickly evaluate antibody pairs in a BsAb format for unique or synergistic functionalities.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre, Vectibix (panitumumab) / Amgen, Takeda
P1 data, Journal: Neratinib plus Cetuximab in Quadruple WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. (Pubmed Central) - Feb 8, 2022
There were no objective responses; SD was seen at all neratinib doses. HER2 amplification, detectable in both tissue and blood, was more frequent post-anti-EGFR therapy.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
PK/PD data, Journal: Bioadhesive chitosan nanoparticles: Dual targeting and pharmacokinetic aspects for advanced lung cancer treatment. (Pubmed Central) - Feb 8, 2022
Surface chemistry analysis by XPS indeed confirmed the successful conjugation of folate and cetuximab on the targeted formulations...In-vivo pharmacokinetic study on Wistar rats has demonstrated improved relative bioavailability of all NP in comparison to DXL control. The results illustrated that EGFR and folate dual targeted NP enhanced the cytotoxicity of DXL towards A-549 lung cancer cells and substantially improved DXL pharmacokinetics in rats.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Feasibility and Efficacy of Neoadjuvant Chemotherapy without Radiotherapy for Locally Advanced Rectal Cancer. (Pubmed Central) - Feb 8, 2022
mFOLFOX6 or SOX plus cetuximab was administered to 12 patients with the wild-type RAS gene and FOLFOXIRI or SOXIRI to 18 patients with mutant-type RAS...The response rate of NAC and the proportion of histological anti-tumor effect grade ≥ 2 were 56.7% and 46.7%, respectively. NAC was considered to be a safe, feasible treatment option for LARC.
|
